AI Article Synopsis

  • Trigeminal neuralgia is challenging to manage, often requiring alternative treatments due to issues with first-line medications like carbamazepine.
  • In a case series of six patients, mirogabalin, a new α2δ ligand, led to an average pain reduction of 43.1%, though results varied among patients.
  • While side effects from mirogabalin were generally mild (notably drowsiness and dizziness), its limited efficacy in some cases suggests that further research is needed to fully assess its potential.

Article Abstract

Trigeminal neuralgia presents significant challenges in management, often requiring alternative pharmacotherapy due to resistance or side effects to first-line medications like carbamazepine. This case series investigates the efficacy and safety of mirogabalin, a novel α2δ ligand, in six trigeminal neuralgia patients. Mirogabalin demonstrated varying degrees of pain reduction, with an average Numerical Rating Scale improvement rate of 43.1%. Side effects were generally mild, with drowsiness and dizziness being the most common. Despite limited efficacy in some cases, mirogabalin shows promise as a potential treatment option for trigeminal neuralgia, warranting further investigation. Trigeminal neuralgia, mirogabalin, α2δ lig.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11231895PMC
http://dx.doi.org/10.4317/jced.61552DOI Listing

Publication Analysis

Top Keywords

trigeminal neuralgia
20
side effects
8
mirogabalin
5
trigeminal
5
neuralgia
5
therapeutic efficacy
4
efficacy mirogabalin
4
mirogabalin managing
4
managing trigeminal
4
neuralgia trigeminal
4

Similar Publications

Background: Bilateral trigeminal neuralgia secondary to multiple sclerosis is an extremely rare condition. When Gasserian ganglion block is performed, it is necessary to achieve reliable long-term analgesic effects while avoiding treatment-related complications.

Case Presentation: A 49-year-old male with multiple sclerosis exhibited persistent dull pain and paroxysmal electric shock-like pain in his bilateral maxillary molars and mandible.

View Article and Find Full Text PDF

Tic douloureux, also known as trigeminal neuralgia, is distinguished by recurrent episodes of severe, lancinating pain that affects one or more branches of the trigeminal nerve, representing a prevalent pain syndrome. This condition has an annual incidence rate of 27 per 100,000 individuals. Nevertheless, direct compression caused by vertebrobasilar dolichoectasia (VBD) represents a considerably less frequent etiology of trigeminal neuralgia, with an estimated overall incidence of about 1%.

View Article and Find Full Text PDF

Trigeminal neuralgia (TN) is a debilitating condition affecting the patients' life quality. New therapeutic approaches and novel drugs are required to treat TN. Trazodone being a serotonin antagonist and reuptake inhibitor (SARI) provides neuroprotection, however its role and underlying mechanism in TN or are not clear.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!